As monotherapy for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
As monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.
In combination with obinutuzumab for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
As monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL)
Treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.
No medicines have been found.
